Press

Freedom Biosciences Emerges from Stealth with $10.5 Million Seed Financing to Develop Next-Generation Ketamine and Psychedelic-based Mental Health Treatments

Aug 24 • 4 min read

Freedom Biosciences, a clinical-stage biotechnology platform developing next-generation viable and efficacious ketamine and psychedelic therapeutics, today emerged from stealth with $10.5 million in seed financing. MBX Capital led the round and was joined by PsyMed Ventures, Village Global and The Yale Startup, among others. The new financing will help the company advance its current lead…

Love Pharma Announces Strategic Acquisition of Doc Hygiene Pharmaceuticals Inc.

Aug 24 • 3 min read

LOVE Pharma Inc. (CSE: LUV | FSE: G1Q0) is pleased to announce that it has entered into a definitive agreement (the ‘Agreement’) to acquire Doc Hygiene Pharmaceuticals Inc. (‘Doc Hygiene’) for aggregate consideration of US$300,000 (the ‘Acquisition’). Doc Hygiene has a premium hygiene product line and brand for hygiene and sanitizing needs and a robust e-commerce platform for products…

Innovation1 Biotech Announces Filing of Patent Application for Novel Combination Therapy Targeting Addiction

Aug 24 • 4 min read

Innovation1 Biotech Inc. (OTCQB: IVBT), a small molecule drug discovery company focused on the clinical development of modified Schedule 1 molecules of botanical origin, today announced it has filed a provisional patent application with the United States Patent and Trademark Office (USPTO) covering its novel and proprietary combination therapy targeting the addiction center in the human…

NRx Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Results Focusing on Reactivation & Advancement of its Psychiatry Franchise

Aug 24 • 9 min read

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), (“NRx Pharmaceuticals” or the “Company”), a clinical-stage biopharmaceutical company, today announced its financial results for the second quarter of 2022 and provided a business and clinical update. “During our second quarter, we reactivated clinical development in our psychiatry franchise around our lead compound, NRX-101. NRX-101 has been awarded Breakthrough Therapy designation…

GH Research Reports Second Quarter 2022 Financial Results and Provides Business Updates

Aug 24 • 5 min read

GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the second quarter ended June 30, 2022 and gave updates on its business. Second Quarter 2022 Financial Highlights Cash position Cash was $265.4 million as of June 30, 2022, compared to…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435